Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients
Table 1
Demographic, clinical, and biochemical characteristics of the two study arms at baseline.
Active group ()
Placebo group ()
Age (years)
63 ± 11
62 ± 12
0.65
Male sex (%)
59%
70%
0.27
Current smokers (%)
12%
19%
0.37
Past smokers (%)
45%
41%
0.66
Diabetes (%)
34%
36%
0.82
BMI (kg/m2)
29 ± 5
29 ± 5
0.66
Systolic/diastolic BP (mmHg)
123 ± 16/73 ± 9
129 ± 21/73 ± 11
0.16/0.81
Heart rate (beats/min)
67 ± 8
68 ± 10
0.64
Cholesterol (mg/dL)
164 ± 41
162 ± 43
0.84
HDL cholesterol (mg/dL)
47 ± 11
50 ± 13
0.18
LDL cholesterol (mg/dL)
88 ± 34
88 ± 36
0.91
eGFRCyst (mL/min/1.73m2)
34 ± 12
29 ± 13
0.06
Hemoglobin (g/dL)
12 ± 2
12 ± 2
0.49
Calcium (mmol/L)
2.25 ± 0.12
2.21 ± 0.10
0.16
Phosphate (mmol/L)
1.20 ± 0.19
1.23 ± 0.16
0.29
Parathormone (pg/mL)
102 (81–146)
102 (85–154)
0.70
FGF-23 (pg/mL)
64.7 (52.7–81.2)
78.0 (53.7–103.1)
0.07
1,25-OH vitamin D (pmol/L)
101.4 ± 41.6
93.6 ± 41.8
0.32
25-OH vitamin D (nmol/L)
33 ± 16
38 ± 16
0.19
C-reactive protein (mg/L)
1.18 (0.68–3.02)
2.49 (0.99–3.74)
0.11
S100A12/ENRAGE (ng/mL)
165 (103–469)
175 (88–272)
0.39
Pentosidine (pmol/mL)
43.6 (31.2–108.9)
44.1 (31.2–99.5)
0.87
Human RAGE (pg/mL)
2072 (1571–2984)
2027 (1481–2794)
0.81
Myeloperoxidase (ng/mL)
128.5 (71.5–204.0)
127.8 (91.5–176.8)
0.90
Data are expressed as mean ± SD, median and interquartile range, or percent frequency as appropriate. BMI: body mass index; BP: blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; eGFR: estimated glomerular filtration rate; FGF-23: fibroblast growth factor-23.
